当前位置: X-MOL 学术Expert Rev. Mol. Diagn. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cystatin C as a biomarker of chronic kidney disease: latest developments.
Expert Review of Molecular Diagnostics ( IF 5.1 ) Pub Date : 2020-05-25 , DOI: 10.1080/14737159.2020.1768849
Stefanie W Benoit 1 , Eileen A Ciccia 1, 2 , Prasad Devarajan 1
Affiliation  

ABSTRACT

Introduction

Chronic kidney disease (CKD) is common, occurring in over 10% of individuals globally, and is increasing in prevalence. The limitations of traditional biomarkers of renal dysfunction, such as serum creatinine, have been well demonstrated in the literature. Therefore, augmenting clinical assessment with newer biomarkers, such as serum cystatin C, has the potential to improve disease monitoring and patient care.

Areas covered

The present paper assesses the utility and limitations of serum cystatin C as a biomarker for CKD in light of the current literature.

Expert opinion

Serum cystatin C has been well established as an early and accurate biomarker of CKD that is particularly helpful in patients for whom creatinine is an inadequate marker or for whom more cumbersome methods of glomerular filtration rate (GFR) measurement are impractical. Current research questions are no longer focused on if, but rather when and how often cystatin C should be used in the evaluation of CKD patients. However, transition of all reagents and estimated GFR equations to the newly established International Standard is critical for developing generalizable data.



中文翻译:

胱抑素 C 作为慢性肾病的生物标志物:最新进展。

摘要

介绍

慢性肾病 (CKD) 很常见,发生在全球超过 10% 的个体中,并且患病率正在增加。传统肾功能障碍生物标志物(如血清肌酐)的局限性已在文献中得到充分证明。因此,使用更新的生物标志物(例如血清胱抑素 C)增强临床评估具有改善疾病监测和患者护理的潜力。

覆盖区域

本论文根据当前文献评估了血清胱抑素 C 作为 CKD 生物标志物的效用和局限性。

专家意见

血清胱抑素 C 已被公认为 CKD 的早期准确生物标志物,对于肌酐标记物不足或更繁琐的肾小球滤过率 (GFR) 测量方法不切实际的患者特别有用。当前的研究问题不再集中在是否应使用胱抑素 C 来评估 CKD 患者,而是应何时使用以及多久使用一次。然而,将所有试剂和估计的 GFR 方程转换为新建立的国际标准对于开发可推广的数据至关重要。

更新日期:2020-05-25
down
wechat
bug